Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The study, published Tuesday in The Lancet Oncology, focused on women under 55 with and without a uterus. CBS News medical ...

Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting ...

Researchers evaluated an electronic health record-based intervention that identified patients with metastatic cancer for a multipronged approach to their in-hospital care.

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

A mum who has breast cancer is one of thousands of women who could be "missing out" on life-extending drugs because of the way they are assessed by the health service, a charity has warned. Breast ...

Thousands of women with advanced breast cancer could be denied life-extending drugs because of the "unfair" way they are ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.